Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Metastatic Melanoma
Primary: Intracranial Objective Response Rate (ORR) — 46.4 Percentage of participants
Phase 2 N=9 Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Advanced Merkel Cell Carcinoma · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) — 7.5; 5.5 months
Phase 2 N=12 Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
Lipedema · Dercum Disease
Primary: The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort — 0; 0; 0 Participants
Phase 2 N=237 A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Migraine
Primary: Change From Baseline in the Number of Monthly Migraine Days (MMDs) — -6.2; -6.0; -4.2 days — p=0.0106
Phase 2 N=148 Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Peanut Allergy
Primary: Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC)…
Phase 2 N=61 The Effects of Oxytocin in Obese Adults
Obesity
Primary: Mean Difference in Weight Loss Between Oxytocin and Placebo 8 Weeks After Baseline — 0.20; 0.26 kilogram
Phase 2 N=290 PfSPZ Vaccine Trial in Malian Children
Malaria · Malaria,Falciparum
Primary: Number of Participants With Possibly, Probably, or Definitely Related Serious Adverse Events (SAEs) — 0; 0 Participants
Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Phase 2 N=40 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Time to Disease Progression — 15.2 weeks
Phase 2 N=54 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Colon Adenocarcinoma · ERBB2 Gene Amplification · Rectal Adenocarcinoma
Primary: Progression-free Survival(PFS) — 4.7; 3.7 Months — p=0.44
Phase 2 N=38 RZL-012 for Dercum's Disease Lipomas
Dercum's Disease Lipomas
Primary: Efficacy - Change in Lipomas Dimensions — -15.13; -15.92 percentage of change from baseline
Phase 2 N=14 A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
Advanced Malignancies
Primary: Number of Patients With Adverse Events or Serious Adverse Events — 0; 1; 1; 1 Participants
Phase 2 N=102 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Ductal Breast Carcinoma In Situ · Invasive Breast Carcinoma · Stage 0 Breast Cancer
Primary: Percentages of Participants by EORTC Breast Cosmetic Rating Score at 24 Months Post-radiation Therapy — 17; 26; 24; 11 Participants
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants